

IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

**QUESTIONS AND ANSWERS AHEAD OF THE UPCOMING
ANNUAL GENERAL MEETING TO BE HELD ON 16 OCTOBER 2026**


The Board of Directors of iX Biopharma Ltd. (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the Company’s Annual Report and Notice of Annual General Meeting dated 30 September 2026 in respect of the annual general meeting to be held on 16 October 2026 (the “**AGM**”).

The Company sets out below the questions received from shareholders ahead of the AGM, and the Company’s responses to the questions.

1. What are the expected timelines and next key milestones for the main pipeline products over the next 12 months?


Wafermine: Our sublingual ketamine wafer for moderate-to-severe acute pain. Both routes to market below are funded under the US Department of Defense (DoD) contract awarded in February 2026.

Phase 3 Milestones



- Preparatory Phase 3 enabling toxicology and pharmacokinetic studies are under way.
- In the next 12 months we expect to meet the FDA (Type C meeting) before starting two Phase 3 studies, KET006 and KET007, which follow our Phase 2 design on a larger scale.
- Success would support a New Drug Application for full FDA approval and potential out-licensing of the product.

Emergency use authorisation (EUA)



- In the next 12 months, we anticipate completing the filing of an application to the United States Food and Drug Administration (US FDA).
- Subject to FDA approval, an EUA would allow the Company to supply Wafermine to the US military before full FDA approval.

Other compounded products and business: The Company is preparing to commence the compounding pharmacy business in the US with certain products from its portfolio of around 40 sublingual formulations.

- To accelerate the launch of compounding, relocation of the Company's freeze dry equipment began in June 2026.
- After the equipment is delivered, the Company will install and commission the equipment and conduct training and validation activities to prepare for compounding business launch.

The Company will announce material milestones via SGXNET as they are reached.

2. What is the Group's current cash position, and is it expected to be sufficient for the Group's requirements?

The Group's cash and cash equivalent as at 30 June 2026 as reported in the Annual Report was \$14.74 million. It is expected to be adequate to meet the Group's requirements assuming that there is no new major initiative and / or project.

3. How much of the 15% authority under the iX Employee Share Option Scheme and the iX Performance Share Plan has been utilised to date? What performance conditions apply to the awards?

As of 11 September 2026, an aggregate of 36,356,177 shares awarded under the iX Performance Share Plan had either vested or remained outstanding (excluding lapsed/cancelled awards). This represents approximately 22.2% of the maximum limit of 163,997,321 shares, being 15% of the total number of issued shares (excluding treasury shares and subsidiary holdings) in the capital of the Company as of 11 September 2026. No options have been granted under the iX Employee Share Option Scheme to date.

Awards under the iX Performance Share Plan are granted at the discretion of the Board, and the applicable vesting and performance conditions are determined on a case-by-case basis for each grant. Details of each grant are set out in the respective announcements made by the Company pursuant to Rule 704(32) of the Catalist Rules.

4. What is the status of licensing or partnership discussions, and when might shareholders expect updates?

As mentioned earlier, we are focused on executing the final, pivotal Phase 3 programme for Wafermine. After the successful completion of Phase 3, we will then determine the appropriate form of monetization, including out-licensing.

With regard to the joint venture with Orion Specialty Labs, final terms are being negotiated and the Company will make an announcement when finalised or if there are material developments.

By Order Of The Board
IX BIOPHARMA LTD.

Gwendolin Lee Soo Fern
Company Secretary

10 October 2026

This announcement has been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor").

This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone: (65) 6590 6881.